Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 50,000 Shares

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $1.44 per share, with a total value of $72,000.00.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, January 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.48 per share, with a total value of $74,000.00.
  • On Wednesday, January 8th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.47 per share, with a total value of $73,500.00.
  • On Monday, December 30th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.47 per share, with a total value of $147,000.00.
  • On Friday, December 27th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.49 per share, with a total value of $149,000.00.
  • On Thursday, December 19th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.53 per share, with a total value of $153,000.00.
  • On Tuesday, December 17th, Phillip Md Et Al Frost bought 75,000 shares of Opko Health stock. The stock was bought at an average cost of $1.50 per share, with a total value of $112,500.00.
  • On Wednesday, December 11th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.50 per share, with a total value of $150,000.00.
  • On Monday, December 9th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.59 per share, with a total value of $79,500.00.
  • On Thursday, December 5th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.62 per share, with a total value of $81,000.00.
  • On Monday, December 2nd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.56 per share, with a total value of $78,000.00.

Shares of Opko Health stock traded down $0.01 during trading hours on Tuesday, reaching $1.43. 26,051 shares of the company’s stock were exchanged, compared to its average volume of 3,946,934. The company has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.84. Opko Health Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $3.89. The company has a current ratio of 1.08, a quick ratio of 0.90 and a debt-to-equity ratio of 0.14. The stock has a market cap of $965.12 million, a P/E ratio of -5.72 and a beta of 2.21.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. The business had revenue of $228.80 million for the quarter, compared to analyst estimates of $225.40 million. During the same quarter in the prior year, the company earned ($0.05) earnings per share. The company’s quarterly revenue was down 8.4% on a year-over-year basis. As a group, analysts expect that Opko Health Inc. will post -0.43 earnings per share for the current fiscal year.

A number of research firms have recently commented on OPK. Piper Jaffray Companies began coverage on shares of Opko Health in a research note on Monday, November 25th. They set an “overweight” rating and a $2.50 price objective for the company. ValuEngine upgraded shares of Opko Health from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Friday, December 20th. Finally, Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $2.83.

Several hedge funds have recently modified their holdings of OPK. Alpha Cubed Investments LLC bought a new stake in shares of Opko Health in the 3rd quarter valued at about $25,000. Kings Point Capital Management bought a new stake in shares of Opko Health in the 2nd quarter valued at about $45,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Opko Health in the 1st quarter valued at about $67,000. Phoenix Holdings Ltd. bought a new stake in shares of Opko Health in the 3rd quarter valued at about $145,000. Finally, Great Point Partners LLC bought a new stake in shares of Opko Health in the 3rd quarter valued at about $193,000. 21.58% of the stock is currently owned by institutional investors.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: What is a capital gain?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.